NCT02175355已完成3 期
A Randomised, Double- Blind, Placebo-controlled, 6 Week Parallel-group Trial on the Efficacy and Safety of the Angiotensin II Receptor Antagonist Micardis® (Telmisartan 20 mg, 40 mg or 80 mg, p.o. Once Daily) or Hydrochlorothiazide 12.5 mg p.o. Once Daily in the Management of Patients With Isolated Systolic Hypertension (ISH). (ARAMIS - Study = Angiotensin II Receptor Antagonist Micardis in Isolated Systolic Hypertension)
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 1,039
- 主要终点
- Change from baseline in urine albumine excretion rate
研究概览
简要总结
Primary: To identify doses of Micardis®(telmisartan) which, administered once daily, are more effective than placebo and not inferior to HCTZ in lowering systolic blood pressure (SBP) in patients with isolated systolic hypertension (ISH), and to assess the dose response relationship of the antihypertensive effect of telmisartan over the dose range of 20 to 80 mg.
Secondary: Target fall in SBP, change from baseline in seated DBP. Safety and tolerability of Micardis® and HCTZ in patients with ISH as measured by changes in physical examinations, heart rate, laboratory parameters and/or 12-lead ECG, as well as the incidence and severity of adverse events.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 35 Years 至 84 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •At least 35 years, but less than 85 years of age
- •Mean SBP ≥ 150 mm Hg and mean DBP < 90 mm Hg at the randomisation visit (visit 2), according to WHO definitions of ISH (excluding the subgroup of borderline ISH)
- •Hypertensive patients not on current antihypertensive therapy or able to stop current treatment for a period of up to 8 - 10 weeks without endangering the health of the patient (investigator's discretion)
- •Ability to provide written informed consent
排除标准
- •Pre-menopausal women (last menstruation ≤ 1 year prior to start of run-in period) who:
- •are not surgically sterile; and/or
- •are nursing
- •are of child-bearing potential and are not practicing acceptable means of birth control or do NOT plan to continue using this method throughout the study. Acceptable methods of birth control include oral, implantable or injectable contraceptives
- •Mean systolic blood pressure ≥ 180 mmHg at the randomization Visit 2
- •Known or suspected secondary hypertension
- •Hepatic and/or renal dysfunction as defined by the following laboratory parameters:
- •Serum glutamic pyruvate transaminase (ALT) or serum glutamic oxaloacetic transaminase (AST) > than 2 times the upper limit of normal range
- •Serum creatinine > or 1.8 mg/dl (or 159 µmol/l)
- •Bilateral renal artery stenosis; renal artery stenosis in a solitary kidney, patients post-renal transplant or with only one functioning kidney
- •Clinically relevant hypokalemia or hyperkalemia
- •Uncorrected volume or sodium depletion
- •Primary aldosteronism
- •Hereditary fructose intolerance
- •Biliary obstructive disorders
- •Symptomatic congestive heart failure
- •Angina pectoris or previous myocardial infarction
- •Previous percutaneous transluminal coronary angioplasty or coronary artery bypass craft
- •Previous cerebrovascular accident or hypertensive encephalopathy or transient ischemic attack(s)
- •Current treatment with any antihypertensive agents, whether or not prescribed for this indication, that cannot be safely stopped (investigators decision) by the start of the run-in period. Any pre-treatment with diuretics, ACE inhibitors or angiotensin II receptor antagonists requires an extension of the run-in period from 2 to 4 weeks for adequate wash-out
- •Atrial fibrillation (controlled or otherwise) or any other clinically relevant cardiac arrhythmias as determined by the clinical investigator
- •Hemodynamically relevant aortic or mitral valve stenosis, obstructive hypertrophic cardiomyopathy or other outflow obstruction of the left ventricle
- •Patients with non-insulin-dependent diabetes mellitus requiring treatment with oral hypoglycemics who fail to meet the following criteria by history:
- •Fasting blood glucose less than 200 mg/dl (11.1 mmol/l)
- •Therapy stabilized for at least one month prior to start of placebo run-period
- •Patients with diabetes mellitus requiring treatment with insulin
- •Patients who have previously experienced symptoms characteristics of angioedema during treatment with ACE inhibitors or angiotensin II receptor antagonists
- •Known drug or alcohol dependency
- •Any investigational therapy within one month of signing the informed consent form and during the trial
- •Known hypersensitivity to any component of the formulation of telmisartan or hydrochlorothiazide including allergy to sulfonamides
- •Concomitant use of lithium or cholestyramine or colestipol resins (potential drug interactions with HCTZ)
- •Gout (contraindication for treatment with HCTZ)
- •Any other clinical condition which, in the opinion of the principal investigator, would not allow safe completion of the protocol and safe administration of telmisartan or hydrochlorothiazide
研究组 & 干预措施
High dose of Micardis®
Experimental
干预措施: High dose of Micardis® (Drug)
Hydrochlorothiazide
Active Comparator
干预措施: Hydrochlorothiazide (Drug)
Placebo
Placebo Comparator
干预措施: Placebo (Drug)
Low dose of Micardis®
Experimental
干预措施: Low dose of Micardis® (Drug)
Medium dose of Micardis®
Experimental
干预措施: Medium dose of Micardis® (Drug)
结局指标
主要结局
Change from baseline in urine albumine excretion rate
时间窗: after 6 weeks of treatment
Change from baseline in seated systolic blood pressure at trough (24 hours post-dose)
时间窗: after 6 weeks of treatment
Change from baseline in pulse wave velocity
时间窗: after 6 weeks of treatment
次要结局
- Change from baseline in augmentation index(after 6 weeks of treatment)
- Incidence and intensity of adverse events(up to 6 weeks)
- Number of patients with relevant changes in 12-lead electrocardiogram (ECG)(up to 6 weeks)
- Percentage of patients achieving a target fall in SBP(after 6 weeks of treatment)
- Changes in seated diastolic blood pressure (DBP)(up to 6 weeks)
- Number of patients with relevant changes from baseline in physical examination(baseline, week 6)
- Number of patients with relevant changes in Heart Rate (HR)(up to 6 weeks)
- Number of patients with relevant changes in laboratory parameters(up to 6 weeks)
研究者
相似试验
已完成
4 期
Telmisartan vs. Valsartan in Patients With Mild to Moderate Hypertension Following a Missed DoseHypertensionNCT00034840Boehringer Ingelheim490
已完成
4 期
INNOVATION Study - Telmisartan (Micardis) in Incipient Diabetic NephropathyDiabetic NephropathiesNCT00153088Boehringer Ingelheim527
已完成
不适用
Observation of Therapy With Micardis® (Telmisartan) in Patients With Essential Hypertension in HospitalsHypertensionNCT02238262Boehringer Ingelheim2,318
已完成
不适用
Micardis® in Patients With Essential HypertensionHypertensionNCT02187705Boehringer Ingelheim1,688
已完成
4 期
A Trial Comparing MICARDIS® (Telmisartan) and COZAAR® / LORZAAR® (Losartan) in Patients With Mild-to-Moderate Hypertension Using Ambulatory Blood Pressure Monitoring (ABPM)HypertensionNCT02200653Boehringer Ingelheim387